About Adenylosuccinate lyase
Adenylosuccinate lyase (ADSL) is a protein
from Homo sapiens identified by UniProt accession
P30566, 484 residues long.
MolForge cross-references it against 0 known binders and
455 disease associations.
Target properties
| Protein name | Adenylosuccinate lyase |
| UniProt accession | P30566 |
| Gene | ADSL |
| Organism | Homo sapiens |
| Length | 484 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (455)
Diseases linked to this target (Open Targets).
- adenylosuccinate lyase deficiency · score 0.85
- neurodegenerative disease · score 0.53
- genetic disorder · score 0.48
- Intellectual disability · score 0.46
- Epileptic encephalopathy · score 0.46
- Progressive neurologic deterioration · score 0.43
- Inability to walk · score 0.43
- Difficulty standing · score 0.43
- Generalized myoclonic seizure · score 0.43
- Severe global developmental delay · score 0.43
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P30566-F1 | alphafold | PREDICTED | 96.55 | — |
Amino-acid sequence (484 residues)
MAAGGDHGSP DSYRSPLASR YASPEMCFVF SDRYKFRTWR QLWLWLAEAE QTLGLPITDE QIQEMKSNLE NIDFKMAAEE EKRLRHDVMA HVHTFGHCCP KAAGIIHLGA TSCYVGDNTD LIILRNALDL LLPKLARVIS RLADFAKERA SLPTLGFTHF QPAQLTTVGK RCCLWIQDLC MDLQNLKRVR DDLRFRGVKG TTGTQASFLQ LFEGDDHKVE QLDKMVTEKA GFKRAFIITG QTYTRKVDIE VLSVLASLGA SVHKICTDIR LLANLKEMEE PFEKQQIGSS AMPYKRNPMR SERCCSLARH LMTLVMDPLQ TASVQWFERT LDDSANRRIC LAEAFLTADT ILNTLQNISE GLVVYPKVIE RRIRQELPFM ATENIIMAMV KAGGSRQDCH EKIRVLSQQA ASVVKQEGGD NDLIERIQVD AYFSPIHSQL DHLLDPSSFT GRASQQVQRF LEEEVYPLLK PYESVMKVKA ELCL
Explore Adenylosuccinate lyase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets